…mportant 5-10 years after diagnosis (Tremlett et al. Neurology 2009;73:1616-1623; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC2881858/pdf/7121.pdf). This suggests that there is a limited time window to potentially alter the disease course with the current immunomodulatory therapies. The times to EDSS 6 or 7 in the Brazilian study are similar to those reported by the Lyons group (23.1 years for EDSS 6, 33.1 years for EDSS 7) (Confavreux…

…determined for three anti-EBV antibodies: anti-EBV nuclear antigen 1 (anti-EBNA-1) or EBNA complex; antiviral capsid antigen (anti-VCA); and anti-Early Antigen (anti-EA). The median seroprevalence of anti-EBNA IgG was 98% in MS patients compared to 88% in controls (odds ratio 4.7). The median anti-VCA IgG seropositivity was 99% in MS patients versus 92% in controls (OR 4.51). In contrast, the median seroprevalence for anti-EA IgG was similar in c…